×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LXRX – lexicon pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LXRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/30
02:50 am
lxrx
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
High
Report
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
1/29
04:31 pm
lxrx
Lexicon Announces Proposed Public Offering of Common Stock
High
Report
Lexicon Announces Proposed Public Offering of Common Stock
1/27
08:33 am
lxrx
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
Medium
Report
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
1/23
08:43 am
lxrx
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary [Yahoo! Finance]
1/23
08:30 am
lxrx
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
Medium
Report
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
1/22
03:21 pm
lxrx
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward [Seeking Alpha]
Low
Report
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward [Seeking Alpha]
1/21
08:30 am
lxrx
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
High
Report
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
1/12
07:30 am
lxrx
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
07:30 am
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
4.4%
lexicon pharmaceuticals, inc.
8/6/2025
07:30 am
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
8.5%
lexicon pharmaceuticals, inc.
5/13/2025
04:00 pm
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
-15.6%
lexicon pharmaceuticals, inc.
3/6/2025
04:00 pm
lxrx
lexicon pharmaceuticals, inc.
BEAT
Report
6.6%
lexicon pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/30
06:08 am
lxrx
Form FWP LEXICON PHARMACEUTICALS, Filed by: LEXICON PHARMACEUTICALS, INC.
High
Report
Form FWP LEXICON PHARMACEUTICALS, Filed by: LEXICON PHARMACEUTICALS, INC.
1/30
06:06 am
lxrx
Form FWP LEXICON PHARMACEUTICALS, Filed by: LEXICON PHARMACEUTICALS, INC.
High
Report
Form FWP LEXICON PHARMACEUTICALS, Filed by: LEXICON PHARMACEUTICALS, INC.
1/29
04:38 pm
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Jan 29
High
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Jan 29
1/29
04:35 pm
lxrx
Form 424B5 LEXICON PHARMACEUTICALS,
High
Report
Form 424B5 LEXICON PHARMACEUTICALS,
11/10
04:31 pm
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 06
Medium
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 06
11/6
05:30 pm
lxrx
Form 424B5 LEXICON PHARMACEUTICALS,
Medium
Report
Form 424B5 LEXICON PHARMACEUTICALS,
11/6
04:57 pm
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 06
High
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 06
11/6
04:13 pm
lxrx
Form 10-Q LEXICON PHARMACEUTICALS, For: Sep 30
High
Report
Form 10-Q LEXICON PHARMACEUTICALS, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/2
Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drug [MarketWatch]
58.0%
9/17 Form 4 LEXICON PHARMACEUTICALS, For: Sep 13 Filed by: SOBECKI CHRISTOPHER J 27.9%
9/10 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting 27.9%
8/8 Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes 15.0%
4/24 Form 4 LEXICON PHARMACEUTICALS, For: Apr 22 Filed by: MAIN ALAN J 11.6%
8/2 Form 4 LEXICON PHARMACEUTICALS, For: Aug 02 Filed by: BARKER SAM L 10.8%
7/29 Here's Why Lexicon Pharmaceuticals Is Collapsing Today [The Motley Fool] 8.7%
12/5 Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 7.4%
6/27 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
10/31 Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 6.3%
9/17 Form 4 LEXICON PHARMACEUTICALS, For: Sep 13 Filed by: SOBECKI CHRISTOPHER J 27.9%
9/10 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting 27.9%
8/8 Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes 15.0%
4/24 Form 4 LEXICON PHARMACEUTICALS, For: Apr 22 Filed by: MAIN ALAN J 11.6%
8/2 Form 4 LEXICON PHARMACEUTICALS, For: Aug 02 Filed by: BARKER SAM L 10.8%
7/29 Here's Why Lexicon Pharmaceuticals Is Collapsing Today [The Motley Fool] 8.7%
12/5 Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 7.4%
6/27 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
10/31 Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 6.3%
TOP News Decliners
7/26
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
-43.7%
7/31 Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update -21.1%
3/19 LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM -15.9%
4/28 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -14.9%
3/12 Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.760 ActVsEst 0.280 - Beat -11.9%
11/7 Form S-3 LEXICON PHARMACEUTICALS, -11.6%
9/19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
12/2 Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes -10.5%
8/1 Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 -9.1%
4/15 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -9.0%
7/31 Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update -21.1%
3/19 LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM -15.9%
4/28 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -14.9%
3/12 Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.760 ActVsEst 0.280 - Beat -11.9%
11/7 Form S-3 LEXICON PHARMACEUTICALS, -11.6%
9/19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
12/2 Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes -10.5%
8/1 Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 -9.1%
4/15 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: